Research
Hormonal
Sibutramine and rimonabant produce greater weight loss than orlistat but carry distinct adverse effect profiles: sibutramine increases blood pressure and heart rate, while rimonabant increases the risk of mood disorders.
Sibutramine and rimonabant are more effective for weight loss than orlistat but have distinct risks. Sibutramine can raise blood pressure and heart rate, requiring monitoring. Rimonabant can increase the risk of mood disorders, requiring careful psychiatric screening. These risks must be weighed against the greater weight loss benefits.
GoodQualifiesHIGH confidence
Sibutramine lowered concentrations of high density lipoprotein cholesterol and triglycerides but raised blood pressure and pulse rate. Rimonabant improved concentrations of high density lipoprotein cholesterol and triglycerides, blood pressure, and glycaemic control in patients with diabetes but increased the risk of mood disorders.
Why this rating
Meta-analysis of 10 sibutramine and 4 rimonabant trials.
Source
Long term pharmacotherapy for obesity and overweight: updated meta-analysis
Diana Rucker et al. · BMJ · 2007
DOI 10.1136/bmj.39385.413113.25
Meta-analysis · 30 studiesCited 799×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Long-term pharmacotherapy with orlistat, sibutramine, or rimonabant produces modest but statistically significant weight loss (2.9–4.7 kg) compared to placebo in adults with obesity, while improving specific cardiovascular risk factors.Good
- Orlistat improves cardiovascular risk factors, including reducing the incidence of type 2 diabetes and improving lipid profiles, despite causing gastrointestinal side effects.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →